

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 2 1 2002

Transworld Mobility Distribution, LLC Mr. Juan C. Rivera President 6140 Mid Metro Drive, Suite 6 Fort Meyers, Florida 33912

Re: K020002

Trade Name: P-33, Battery Operated, Three-Wheel Electric Scooter

Regulation Number: 890.3800

Regulation Name: Motorized Three-Wheeled Vehicle

Regulatory Class: II Product Code: INI

Dated: December 30, 2001 Received: January 2, 2002

Dear Mr. Rivera:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,
Mark Millserse

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indications for Use Statement

The intended use of the P-33 is to provide mobility to adults with the

510K number: K020002

Indications For Use:

Device Name: Model P-33, Three Wheel Electric Scooter

			**		
			,		
• .					
					-
	TE BELOW THIS LI	NE-CONT	INUE ON A	NOTHER	PAGE IF
EDED)					PAGE IF
EDED)	TTE BELOW THIS LIP				PAGE IF
EDED)	ncurrence of CDRH, Offic	e of Device I			PAGE IF
EDED)	ncurrence of CDRH, Offic	e of Device I			PAGE IF
EDED)	ncurrence of CDRH, Offic (Division Division of	e of Device I	Evaluation (OD		PAGE IF
EDED)	(Division of and Neuro	Sign-Off) of General, ological De	Evaluation (OD		PAGE IF